<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> is accompanied by a robust <z:mp ids='MP_0001845'>inflammatory response</z:mp>, <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>-mediated excitotoxicity, release of reactive oxygen species and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi>, which target the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-g, have been reported recently to exhibit potent anti-inflammatory and anti-oxidant actions and inhibit both neural excitotoxicity and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>2 </plain></SENT>
<SENT sid="4" pm="."><plain>The present study was conducted to determine whether <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, a potent thiazolidinedione for PPAR-g, would show efficacy against the <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and neurological dysfunctions induced by embolic middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion in the rat </plain></SENT>
<SENT sid="5" pm="."><plain>3 </plain></SENT>
<SENT sid="6" pm="."><plain>Focal ischaemic injury was induced by embolizing a preformed clot into the <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> was dissolved in <z:chebi fb="0" ids="28262">dimethyl sulphoxide</z:chebi> and injected i.p </plain></SENT>
<SENT sid="8" pm="."><plain>1 h before <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion at doses of 0.33, 0.1, 0.3 or 1 mg/kg </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, 1 mg/kg <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> was used immediately or 4 h after embolization </plain></SENT>
<SENT sid="10" pm="."><plain>Forty-eight hours after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, brains were removed, sectioned and stained with a 2% solution of 2,3,5-triphenyltetrazolum <z:chebi fb="76" ids="17996">chloride</z:chebi> and analysed using a commercial image-processing software program </plain></SENT>
<SENT sid="11" pm="."><plain>4 </plain></SENT>
<SENT sid="12" pm="."><plain>When <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> was administered 1 h before embolization, it significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 48.2, 68.4% and 70.3% at doses of 0.1, 0.3 and 1 mg/kg, respectively (P &lt; 0.001) </plain></SENT>
<SENT sid="13" pm="."><plain>Administration of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (1 mg/kg) immediately or 4 h after <z:hpo ids='HP_0001297'>stroke</z:hpo> also reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 67 and 50.8%, respectively (P &lt; 0.001) </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi>-treated rats also demonstrated improved neurological functions </plain></SENT>
<SENT sid="15" pm="."><plain>However, there were no statistically significant differences between control and treated groups in terms of <z:hpo ids='HP_0002181'>brain oedema</z:hpo> at 48 h after ischaemic injury </plain></SENT>
<SENT sid="16" pm="."><plain>5 </plain></SENT>
<SENT sid="17" pm="."><plain>The findings of the present study may support the idea of a potential benefit of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> in the management of ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>